PRAN vs. LPTX, XBIT, ATOS, ANRO, IVA, NVCT, VERU, INZY, ENTA, and IGMS
Should you be buying Alterity Therapeutics stock or one of its competitors? The main competitors of Alterity Therapeutics include Leap Therapeutics (LPTX), XBiotech (XBIT), Atossa Therapeutics (ATOS), Alto Neuroscience (ANRO), Inventiva (IVA), Nuvectis Pharma (NVCT), Veru (VERU), Inozyme Pharma (INZY), Enanta Pharmaceuticals (ENTA), and IGM Biosciences (IGMS). These companies are all part of the "medical" sector.
Alterity Therapeutics vs.
Leap Therapeutics (NASDAQ:LPTX) and Alterity Therapeutics (NASDAQ:PRAN) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their risk, institutional ownership, media sentiment, dividends, valuation, earnings, profitability, community ranking and analyst recommendations.
Leap Therapeutics presently has a consensus target price of $7.50, suggesting a potential upside of 204.88%. Given Leap Therapeutics' stronger consensus rating and higher probable upside, equities analysts clearly believe Leap Therapeutics is more favorable than Alterity Therapeutics.
30.5% of Leap Therapeutics shares are held by institutional investors. Comparatively, 3.6% of Alterity Therapeutics shares are held by institutional investors. 5.4% of Leap Therapeutics shares are held by insiders. Comparatively, 38.8% of Alterity Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Alterity Therapeutics' return on equity of 0.00% beat Leap Therapeutics' return on equity.
In the previous week, Leap Therapeutics had 3 more articles in the media than Alterity Therapeutics. MarketBeat recorded 3 mentions for Leap Therapeutics and 0 mentions for Alterity Therapeutics. Leap Therapeutics' average media sentiment score of 0.61 beat Alterity Therapeutics' score of 0.00 indicating that Leap Therapeutics is being referred to more favorably in the media.
Alterity Therapeutics has higher revenue and earnings than Leap Therapeutics. Alterity Therapeutics is trading at a lower price-to-earnings ratio than Leap Therapeutics, indicating that it is currently the more affordable of the two stocks.
Leap Therapeutics received 106 more outperform votes than Alterity Therapeutics when rated by MarketBeat users. Likewise, 69.01% of users gave Leap Therapeutics an outperform vote while only 57.67% of users gave Alterity Therapeutics an outperform vote.
Leap Therapeutics has a beta of 0.17, suggesting that its stock price is 83% less volatile than the S&P 500. Comparatively, Alterity Therapeutics has a beta of 1.05, suggesting that its stock price is 5% more volatile than the S&P 500.
Summary
Leap Therapeutics beats Alterity Therapeutics on 8 of the 15 factors compared between the two stocks.
Get Alterity Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for PRAN and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Alterity Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:PRAN) was last updated on 1/22/2025 by MarketBeat.com Staff
Free PRAN Stock Alerts